Targeting patients for statin therapy for the primary prevention of vascular events: What is the best approach?

Circulation

Volumn 122, Issue 15, 2010, Pages 1446-1448

  Mahoney, Elizabeth M ^a  

^a Saint Luke's Mid America Heart and Vascular Institute   (United States)

Author keywords

c reactive protein; cost benefit analysis; Editorials; primary prevention; statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EDITORIAL; HEALTH CARE POLICY; HEART INFARCTION; HUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK MANAGEMENT; STROKE; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; BLOOD; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE PLANNING; METABOLISM; MYOCARDIAL INFARCTION; PATIENT SELECTION; RISK;

C-REACTIVE PROTEIN; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH PLANNING GUIDELINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PATIENT SELECTION; RISK; STROKE;

EID: 77958459735     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.981944     Document Type: Editorial

References (18)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk indi-viduals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
2. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243-254.
3. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuv-astatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med. 2008;359:2195-2207.
4. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and car-diovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
5. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70
6. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation. 2009;2:65-72.
7. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Opti-mizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152:69-77.
8. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
9. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26:799-806.
10. Nambi V, Ballantyne CM. "Risky business": ten years is not a lifetime. Circulation. 2009;119:362-364.
11. Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate-and low-cardiovascular-risk individuals for statin therapy. Circulation. 2010;122:1478-1487.
12. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 par-ticipants in 14randomisedtrials of statins. Lancet. 2005;366:1267-1278.
13. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH; STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T. Stopping ran-domized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303: 1180-1187.
14. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
15. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Mul-tinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009;120:2188-2196.
16. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF, Shea S, Sidney S, O'Leary DH, Chan C, Lloyd-Jones DM. Prevalence and pro-gression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multiethnic study of atherosclerosis. Circulation. 2009;119:382-389.
17. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovas-cular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.
18. Yusuf S, Anand S. Cost of prevention. The case of lipid lowering. Circulation. 1996;93:1774-1776.